Released Aug 4, 2016, after the close
10-Q filed Aug 4, 2016, 35 days after period end · 0001171843-16-011528
Q2 2016 · 10-Q
Revenue$26.14M$26.14M −9.3% vs Q2 2015−3.1% vs Q1 2016
Net Income-$713.00K-$713.00K N/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.02-$0.02 N/M vs Q2 2015N/M vs Q1 2016
Gross Profit$11,675,000−7.3%
Operating Income-$840,000N/M
Operating Cash Flowderived$942,000N/M
Margins · derived
Gross margin44.7%+0.9 pt vs Q2 2015
Operating margin-3.2%−3.6 pt vs Q2 2015
Net margin-2.7%−3.9 pt vs Q2 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2016 | Q2 2015 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue | $26.14M | $28.80M | $26.96M | $26.09M |
| Net Income | -$713.00K | $349.00K | $1.02M | -$186.00K |
| EPS Diluted | -$0.02 | $0.01 | $0.03 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR